Caffeine Blues_ Wake Up to the Hidden Dangers of America's #1 Drug ( PDFDrive )
Page 35
White Lotus Foundation
2500 San Marcos Pass
Santa Barbara, CA 93105
800-544-FLOW
www.whitelotus.org
Yoga instruction, teachers’ training, retreats, videotapes.
Satchidananda Yoga Ashram
Box 172
Route #1
Buckingham, VA 23921
800-969-3121
Certifying Organizations for Fitness Trainers
American College of Sports Medicine
P.O. Box 1440
Indianapolis, IN 46206
317-637-9200
Aerobics and Fitness Association of America
15250 Ventura Blvd, Suite 310
Sherman Oaks, CA 91403
800-446-2322
IDEA International Association of Fitness Professionals 6190 Cornerstone Ct East, Suite 204
San Diego, CA 92121-3773
800-999-4332
LABORATORIES—HORMONE SALIVA TESTS
Aeron Life Cycles
San Leandro, CA
800-631-7900
510-729-0383
Diagnos-Techs, Inc.
6620 S. 192nd Place
Suite J-104
Kent, WA 98032
800-878-3787
206-251-0596
APPENDIX C
Your off the Bean Journal
A RECORD OF YOUR SUCCESS IN REDUCING OR ELIMINATING
CAFFEINE FROM YOUR DIET
Before you begin your Off the Bean program, answer the following questions. Make a copy of this evaluation first so that you can retest yourself at thirty-, sixty-, and ninety-day intervals:
DATE:_______
1. Using the information in Chapter 2, calculate how much caffeine you consume daily.
<100 mg 200 mg 300 mg 400 mg 500 mg >600 mg 2. Note any of the following symptoms you suffer from: Score a “1” for occasional, “2” for frequently, and “3” for constant.
Emotions
—Anxiety/nervousness —Irritability, anger, or aggressiveness —Mood swings
—Depression
—Poor concentration —Panic attacks
Digestion
—Ulcers
—Acid indigestion —Heartburn
—Bloating/gas
—Diarrhea
—Colitis
—Irritable bowel syndrome Heart
—Irregular or rapid heartbeat —High blood pressure Skin —Skin rashes
—Aging skin
—Dry skin
General
—Gout
—Candida/yeast infections —Neck, shoulder, or back pain —High cholesterol —Bladder/Urinary tract infections Other
—__________________________
—__________________________
Energy
—Energy swings
—Fatigue, sluggishness —Poor concentration —Restlessness —Hyperactivity
Head
—Tension headache —Migraine
—Dizziness
—Tinnitus (Ringing in the ears) Blood Sugar
—[Diabetics] Wide blood sugar swings —Low blood sugar
Sleep
—Difficulty falling asleep —Difficulty staying asleep —Tired upon arising Women’s Health
—Premenstrual tension (PMS) —Fibrocystic breast disease —Low iron Men’s Health
—Enlarged prostate —Urinary symptoms TOTAL SCORE:___
3. Note any particular times of the day when your energy routinely slumps: Upon arising
8–9 A.M.
10–11 A.M.
12–1 P.M.
2–3 P.M.
4–5 P.M.
6–7 P.M.
8–9 P.M.
4. How often do you exercise?
0–1 × week
2–4 × week
5+ × week
5. How long do you exercise?
10–15 minutes
15–30 minutes
30+ minutes
6. How intense is your exercise?
easy
medium
hard
7. How do you feel after you exercise?
exhausted
tired
invigorated
8. How would you rate your energy level?
low
medium
high
9. Are you alert upon awakening?
never
sometimes
often
10. How would you rate your ability to cope with stress?
low
medium
high
11. Do you experience sugar cravings?
frequently
sometimes
never
12. Rate your mental clarity.
foggy
average
sharp
13. Rate your overall emotional state.
depressed
erratic
balanced
Retest yourself thirty days, sixty days, and ninety days after initiating your Off the Bean program. Compare your score and progress. Note below any observations or improvements you experience that aren’t covered above:
NOTES
Introduction
1
M. L. Arbeit, T. A. Nicklas, G. C. Frank et al., “Caffeine Intakes of Children from a Biracial Population: The Bogalusa Heart study,” Journal of the American Dietetic Association, April 1988;88(4):466–71. (back to text) Chapter 1
1
S. Y. Tse, “Cholinomimetic Compound Distinct from Caffeine Contained in Coffee II: Muscarinic Actions,” Journal of Pharmaceutical Sciences, May 1992;81 (5):449–52. (back to text)
2
World Health Organization International Agency for Research on Cancer, “Coffee, Tea, Mate, Methylxanthines, and MetJiylgloxal,” International Agency for Research on Cancer Monograph Evaluation of Carcinogen Risks in Humans, 1991;51:1–513. (back to text)
3
R. M. Gilbert, “Caffeine as a Drug of Abuse,” in R. J. Gibbins et al. (eds.), Research Advances in Alcohol and Drug Problems (New York: John Wiley &
Sons, 1976), pp. 49–176. (back to text)
4
R. N. Warren, “Metabolism of Xanthine Alkaloids in Man,” Journal of Chromatography, 1969;40:468–69. (back to text)
5
J. J. Barone and H. R. Roberts, “Caffeine Consumption,” Food and Chemical Toxicology, 1996;34(1):119–29. (back to text)
6
A. Koczapski, J. Paredes, C. Kogan et al., “Effects of Caffeine on Behavior of Schizophrenic Inpatients,” Schizophrenia Bulletin, 1989;15(2):339–44. (back to text)
7
P. B. Lucas, D. Pickar, J. Kelsoe et al., “Effects of the Acute Administration of Caffeine in Patients with Schizophrenia,” Biological Psychiatry, 1990;28(1):35–40. (back to text)
8
B. Stavric, R. Klasses, B. Watkinson et al., “Variability in Caffeine Consumption from Coffee and Tea: Possible Significance for Epidemiological Studies,” Food and Chemical Toxicology, 1988;26:111–18. (back to text) 9
R. M. Gilbert, J. A. Marshman, M. Schwieder et al., “Caffeine Content of Beverages as Consumed,” Canadian Medical Association Journal, 1976;114:205–08. (back to text)
Chapter 2
1
“Combating Caffeine’s Arrhythmogenic Potential,” Postgraduate Medicine, 1992;9(1):57–58. (back to text)
2
Food and Drug Administration, Caffeine Content of Various Products, FDA, Washington, D.C. Paper T80-45, 1980. (back to text)
3
“Coffee Craze Stirs Up Some New Headaches,” Family Practice News, 1996;26(6):21. (back to text)
4
G. Bovim, P. Naess, J. Helle et al., “Caffeine Influence on the Motor Steadiness Battery in Neuropsychological Tests,” Journal of Clinical and Experimental Neuropsychology, May 1995;17(3):472–76. (back to text) 5
M. J. Shirlow and C. D. Mathers, “A Study of Caffeine Consumption and Symptoms: Indigestion, Palpitations, Tremor, Headache and Insom
nia,”
International Journal of Epidemiology, June 1985;14(2):239–48. (back to text) 6
V. Saano and M. M. Airaksinen, “Binding of Beta-carbolines and Caffeine on Benzodiazepine Receptors: Correlations to Convulsions and Tremor,” Acta Pharmacologica et Toxicologica, Copenhagen, October 1982;51(4):300–08.
(back to text)
7
B. H. Jacobson, K. Winter-Roberts, and H. A. Gemmell, “Influence of Caffeine on Selected Manual Manipulation Skills,” Perceptual and Motor Skills, June 1991;72(Pt 2):1175–81. (back to text)
8
J. R. Hughes, S. T. Higgins, W. K. Bickel et al., “Caffeine SelfAdministration, Withdrawal, and Adverse Effects among Coffee Drinkers,” Archives of General
Psychiatry, July 1991;48(7):611–17. (back to text)
9
H. Schroeder, H. Siegmund, G. Santibanez et al., “Causes and Signs of Temporomandibular Joint Pain and Dysfunction: An Electromyographical Investigation,” Journal of Oral Rehabilitation, July 1991;18(4):301–10. (back to text)
10
C. J. Pierce, K. Chrisman, M. E. Bennett et al., “Stress, Anticipatory Stress, and Psychologic Measures Related to Sleep Bruxism,” Journal of Orofacial Pain, Winter 1995;9(1):51–56. (back to text)
11
J. R. Hughes, S. T. Higgins, W. K. Bickel et al., “Caffeine SelfAdministration, Withdrawal, and Adverse Effects among Coffee Drinkers,”
Archives of General Psychiatry, July 1991;48(7):611–17. (back to text) 12
E. C. Strain, G. K. Mumford, K. Silverman et al., “Caffeine Dependence Syndrome: Evidence from Case Histories and Experimental Evaluations,”
Journal of the American Medical Association, 1994:272:1043–48. (back to text) Chapter 3
1
R. J. Thomas, “Caffeine and Arrhythmias: What Are the Risks?,” Your Patient & Fitness, 1991;5(5):6–8. (back to text)
2
M. Vincent-Viry, Z. B. Pontes, R. Gueguen et al., “Segregation Analyses of Four Urinary Caffeine Metabolite Ratios Implicated in the Determination of Human Acetylation Phenotypes,” Genetic Epidemiology, 1994;11(2):115—29.
(back to text)
3
J. Soto, M. J. Alsar, and J. A. Sacristan, “Assessment of the Time Course of Drugs with Inhibitory Effects on Hepatic Metabolic Activity Using Successive Salivary Caffeine Tests,” Pharmacotherapy, November 1995;15(6):781—84.
(back to text)
4
C. Stratton, “Fluoroquinolone Antibiotics: Properties of the Class and Individual Agents,” Clinical Therapeutics, May–June 1992;14(3):348–75. (back to text)
5
A. H. Staib, W Stille, G. Dietlein et al., “Interaction between Quinolones and Caffeine,” Drugs, 1987;34 supplement 1:170–74. (back to text) 6
E. Tarrus, E. I. Garcia, D. J. Roberts et al., “An Animal Model for the
Detection of Drug-Induced Inhibition of Caffeine Metabolism,” Methods and Findings in Experimental and Clinical Pharmacology, May 1987:9(5):311–16.
(back to text)
7
R. A. Upton, “Pharmacokinetic Interactions between Theophylline and Other Medication (Part I),” Clinical Pharmacokinetics, January 199l;20(1):66–80.
(back to text)
8
J. O. Miners, “Drug Interactions Involving Aspirin (Acetylsalicylic Acid) and Salicylic Acid,” Clinical Pharmacokinetics, November 1989;17(5):327–44.
(back to text)
9
K. L. Rost and I. Roots, “Accelerated Caffeine Metabolism after Omeprazole Treatment Is Indicated by Urinary Metabolite Ratios: Coincidence with Plasma Clearance and Breath Test,” Clinical Pharmacology and Therapeutics, April 1994;55(4):402–11. (back to text)
10
N. R. Scott, D. Stambuk, J. Chakraborty et al., “Caffeine Clearance and Biotransformation in Patients with Chronic Liver Disease,” Clinical Science, 1988;74:377–84. (back to text)
11
J. A. Swanson, J. W Lee, J. W. Hopp et al., “The Impact of Caffeine Use on Tobacco Cessation and Withdrawal,” Addictive Behaviors, January—February 1997; 22(1):55–68. (back to text)
12
R. Garcia, “The Cardiovascular Effects of Caffeine,” Caffeine, Coffee and Health. S. Garatrini, (ed.), (New York: Raven Press, 1993). (back to text) 13
J. Ferri, “Under Pressure,” The Tampa Tribune-Times, April 27, 1997, pp. 1–2. (back to text)
14
A. Nehlig, J. L. Daval, and G. Debry, “Caffeine and the Central Nervous System: Mechanisms of Action, Biochemical, Metabolic and Psychostimulant Effects,” Brain Research Reviews, May-August 1992;17(2):139–70. (back to text)
15
W. Lovallo, M. Al’Absi, K. Blick et al., “Stress-like Adrenocorticotropin Responses to Caffeine in Young Healthy Men,” Pharmacology, Biochemistry and Behavior, November 1996;55(3):365–69. (back to text) 16
J. M. Nash, “Addicted: Mounting Evidence Points to a Powerful Brain Chemical Called Dopamine,” Time, May 5, 1997, pp. 68–76. (back to text) 17
G. R. Stoner, L. R. Skirboll, S. Werkman et al., “Preferential Effects of
Caffeine on Limbic and Cortical Dopamine Systems,” Biological Psychiatry, April 15, 1988;23(8):761–68. (back to text)
18
J. H. Boublik, M. J. Quinn, J. A. Clements et al., “Coffee Contains Potent Opiate Receptor Binding Activity,” Nature, January 20, 1983;301(5897):246–48. (back to text)
19
J. Zhou, S. Olsen, J. Moldovan et al., “Glucocorticoid Regulation of Natural Cytotoxicity: Effects of Cortisol on the Phenotype and Function of a Cloned Human Natural Killer Cell Line,” Cellular Immunology, June 15, 1997;178(2):108–16. (back to text)
20
I. J. Elenkov, D. A. Papanicolaou, R. L. Wilder et al., “Modulatory Effects of Glucocorticoids and Catecholamines on Human Interleukin-12 and Interleukin10 Production: Clinical Implications,” Proceedings of the Association of American Physicians, September 1996;108(5):374–81. (back to text) 21
R. Glaser, J. K. Kiecolt-Glaser, R. H. Bonneau et al., “Stress-Induced Modulation of the Immune Response to Recombinant Hepatitis B Vaccine,”
Psychosomatic Medicine, January-February 1992;54(1):22–29. (back to text) 22
N. Christeff, N. Gherbi, O. Mammes et al., “Serum Cortisol and DHEA Concentrations During HIV Infection,” Psychoneuroendocrinology, 1997;22
supplement 1:S11–18. (back to text)
23
J. Brind, “Spotlight on DHEA: A Marker for Progression of HIV Infection?”
Journal of Laboratory and Clinical Medicine, June 1996;127(6):522—23. (back to text)
24
P. Salvato et al., “Oral Intake of DHEA Is Associated with Reductions in Viral Load,” International Conference on AIDS, July 7–12, 1996. (back to text) 25
D. C. Mackay and J. W. Rollins, “Caffeine and Caffeinism,” Journal of the Royal Navy Medical Service, 1989;75(2):65–67. (back to text) 26
TD. J. Roca, G. D. Schiller, and D. H. Farb, “Chronic Caffeine or Theophylline Exposure Reduces Gamma-Aminobutyric Acid/Benzodiazepine Receptor Site Interactions,” Molecular Pharmacology, May 1988;33(5):481–85.
(back to text)
27
C. Stratton, “Fluoroquinolone Antibiotics: Properties of the Class and Individual Agents,” Clinical Therapeutics, May–June 1992;14(3):348–75; Discussion 347. (back to text)
28
B. I. Davies and F. P. Maesen, “Drug Interactions with Quinolones,” Review of Infectious Diseases, July–August 1989;11 supplement 5:S1083–90. (back to text)
29
E. B. Truitt, Jr., “The Xantjhines,” in J. R. DiPalma (ed.), Drill’s Pharmacology in Medicine (New York: McGraw-Hill, 1971), pp. 533–56. (back to text)
30
J. M. Ritchie, “Central Nervous Stimulants II: The Xanthines,” in L. S.
Goodman and A. Gilman (eds.), The Pharmacological Basis of Therapeutics (New York: Macmillan, 1970), pp. 358–70. (back to text) 31
&nb
sp; A. Goldstein, L. Aronow, and S. M. Kalman, Principles of Drug Action: The Basis of Pharmacology (New York: Wiley, 1974). (back to text) 32
A. N. Nicholson, A. J. Belyavin, and P. A. Pascoe, “Modulation of Rapid Eye Movement Sleep in Humans by Drugs that Modify Monoaminergic and Purinergic Transmission,” Neuropsychopharmacology, June 1989;2(2):131–43.
(back to text)
33
H. P. Landolt, D. J. Dijk, S. E. Gaus et al., “Caffeine Reduces Low-frequency Delta Activity in the Human Sleep EEG,” Neuropsychopharmacology, May 1995; 12(3):229–38. (back to text)
34
L. J. Dorfman and M. E. Jarvik, “Comparative Stimulant and Diuretic Actions of Caffeine and Theobromine in Man,” Clinical Pharmacology and Therapeutics, 1970;11:869–72. (back to text)
35
A. Goldstein, R. Warren, and S. Kaizer, “Psychotropic Effects of Caffeine in Man I: Individual Differences in Sensitivity to CaffeineInduced Wakefulness,”
Journal of Pharmacology and Experimental Therapeutics, 1965:149:156–59.
(back to text)
36
H. P Landolt, E. Werth, A. A Borbely et al., “Caffeine Intake (200 mg) in the Morning Affects Human Sleep and EEG Power Spectra at Night,” Brain Research, March 27, 1995;675(1–2):67–74. (back to text) 37